Detection and Pathogenesis of Novel Protein F

From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cardiac Disease Blood Protein Disorders Cardiovascular Diseases Disease Heart Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

About this study

Protein F screening was performed on anticoagulant blood plasma with heparin Lithium or blood serum by in-house turbidimetric method in Automatic biochemical analyzer.

All patients were followed-up for 3 years by telephones, routine appointment out-patient clinic or returning visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Testing total protein and albumin
Testing routine blood test

Exclusion criteria

high triglycerides (TG>5.00 mmol/L)
hyperbilirubinemia (TBIL>170 mmol/L)
fat emulsion used in past 3 days
patients with hemolytic disease
pregnant and lactating women

Treatment and study plan

Primary outcomes

Concentration of plasma protein F content

Time frame: six month

the protein F content was measured by turbidimetric assay in automatic biochemical analyzer

Secondary outcomes

Number of Participants with Multiple myeloma

Time frame: 3 years

Develop or be diagnosed with multiple myeloma

Study contacts

Contact information is provided by the study sponsor or research team.

Qingkun Fan, MD

CONTACT

[email protected]

027-65796747

Sponsors and collaborators

Lead sponsor

Wuhan Asia Heart Hospital

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2025
Study completion: 2028
First posted: Apr 8, 2020
Registry last updated: Apr 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting